Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DACIPHOR: Ixazomib + DA-EPOCH-R in MYC-aberrant Lymphoid Malignancies
NCT02481310Phase 2Unknown
- Sponsor
- Northwestern University
- Start
- Oct 2015
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), high grade B-cell lymphoma (HGBCL), sponsored by Northwestern University. Status: unknown.
02
Drugs
ixazomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)plasmablastic lymphoma (PBL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT02481310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481310.